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Abstract 20 
Purpose  The underlying biological mechanisms of the frequent exacerbator 21 
phenotype of COPD remain unclear. We compared systemic neutrophil function in 22 
COPD patients with or without frequent exacerbations.  23 
Methods  Whole blood from COPD frequent exacerbators (defined as ≥ 2 24 
moderate-severe exacerbations in the previous 2 years), and non-exacerbators (no 25 
exacerbations in the preceding 2 years) was assayed for neutrophil function. 26 
Neutrophil function in healthy ex-smoking volunteers was also measured as a control 27 
(reference) group.  28 
Results A total of 52 subjects were included in this study; 26 frequent 29 
exacerbators, 18 non-exacerbators and 8 healthy controls. COPD frequent 30 
exacerbators had blunted blood neutrophil fMLP-stimulated oxidative burst compared 31 
to both non-exacerbators (p < 0.01) and healthy controls (p < 0.001). There were no 32 
differences between COPD frequent exacerbators and non-exacerbators in blood 33 
neutrophil PMA-stimulated oxidative burst but both COPD groups had reduced 34 
responses compared to healthy controls (p < 0.001). Bacterial-stimulated neutrophil 35 
degranulation was greater in frequent exacerbators than non-exacerbators (p < 0.05).  36 
Conclusion This study is the first to report aberrant receptor-mediated blood 37 
neutrophil function in the frequent exacerbator of COPD.  38 
Keywords: chronic obstructive pulmonary disease; elastase; granulocyte; 39 
polymorphonuclear leukocytes; reactive oxygen species.   40 
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Introduction 41 
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive 42 
decline in lung function and associated with chronic aberrant inflammatory responses 43 
of the lung and airways to noxious stimuli [1]. Globally, COPD is now the third leading 44 
cause of mortality [2], and the second leading cause of disability-adjusted life-years 45 
lost [3].  Acute exacerbations (defined as sustained worsening of symptoms beyond 46 
the normal day to day variation that may result in change of medical treatment and/or 47 
hospitalisation) represent one of the primary manifestations of COPD and account for 48 
50% to 75% of the costs associated with disease [4]. More frequent exacerbations 49 
increase the risk of hospitalization, contribute to increased mortality risk during 50 
hospitalisation and are associated with faster decline in lung function and worsening 51 
health related quality of life [1,5,6]. 52 
The Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints 53 
(ECLIPSE) study proposed that frequent exacerbators are a distinct phenotype in the 54 
moderate-severe stages of the disease that is relatively stable over time [7,8]. More 55 
specific phenotyping of COPD appears an increasingly important step towards 56 
improving clinical management [8]. Despite clearer recognition of the frequent 57 
exacerbator phenotype, the underlying biology of the susceptibility to exacerbations 58 
remain unclear [9]. In order to better understand the pathogenesis of exacerbations, 59 
comparisons of patients with none versus frequent exacerbations are required [10]. 60 
As a result of the identification of large alterations in immune related gene expression 61 
within blood of frequent exacerbators [11], researching the pathophysiology of COPD 62 
exacerbations by focusing on changes that occur in the systemic immune 63 
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compartment rather than a specific pulmonary immune defect per se could be fruitful. 64 
Neutrophils, particularly neutrophil-derived proteinases, have been implicated in lung 65 
destruction and remodelling and hence pathogenesis of COPD [12]. Neutrophil count 66 
and neutrophilic inflammatory mediators are higher within the airways, even in the 67 
stable (non-exacerbated) state in COPD [13]. Blood neutrophils also show an altered 68 
pattern of activity in the stable state in COPD, with impaired chemotaxis and reduced 69 
intracellular reactive oxygen species (ROS) production [14-16]. Evidence of further 70 
systemic immune dysregulation occurs during exacerbations with circulating 71 
neutrophils displaying up-regulation of inflammation related genes, enhanced 72 
expression of cell adhesion molecules and elevated production of elastase and ROS 73 
[17-20]. Despite an abundance of data supporting the hypothesis that neutrophils are 74 
key effector cells in the development and progression of COPD [13], we could find no 75 
studies assessing blood neutrophil function of COPD patients according to 76 
exacerbation history.  77 
To better establish the biological underpinning of the frequent exacerbator and 78 
ultimately direct development of novel therapies for this high-risk group of patients, 79 
we need an improved understanding of the changes in systemic immune function 80 
associated with this phenotype. With this in mind, this proof of concept study was 81 
designed to characterise blood neutrophil function of COPD patients in a stable state 82 
with or without a history of frequent exacerbations. The primary aim of this study was 83 
to test the null hypothesis that there is no difference in in vitro blood neutrophil 84 
function between COPD frequent exacerbators, COPD non-exacerbators and healthy 85 
controls. 86 
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Methods 87 
Study design and participants  88 
Following loco-regional ethics approval, 44 patients with COPD, defined as over 40 89 
years, at least 10 pack year smoking history and post-bronchodilator (100 mcg of 90 
inhaled salbutamol) FEV1<80% predicted with FEV1/FVC ratio<0.70 [1], were 91 
prospectively recruited from outpatient clinics of a UK district hospital.  92 
Current symptoms (cough, sputum), exacerbation history, co-morbidities, prescribed 93 
medications and smoking history were collected at interview. Participants underwent 94 
clinical examination and spirometry (Vitalograph Alpha®, Vitalograph Ltd., UK). 95 
Frequent exacerbators were patients who had 2 or more exacerbations requiring oral 96 
corticosteroids and/or antibiotics during the last 2 years, and/or attendance to 97 
hospital [1]. Patients were deemed non-exacerbators if they had not attended hospital 98 
nor required systemic treatments for their COPD during the previous 2 years. Self-99 
reports were confirmed through hospital records and GP prescriptions. Eight healthy, 100 
ex-smokers who had no symptoms of lung disease and had normal spirometry were 101 
recruited as a control (reference) group. Informed consent was obtained from all 102 
individual participants included in the study. 103 
We excluded current smokers defined as anyone reporting smoking a cigarette within 104 
6 months or having an exhaled carbon monoxide (eCO) >10 parts per million 105 
(MicroCO, CareFusion Ltd.UK) on the day of testing. We also excluded anyone with 106 
known structural lung disease (asthma, bronchiectasis, pulmonary fibrosis); cancer 107 
(other than non-melanotic skin cancer); severe renal failure (calculated eGFR less 108 
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than 60 ml/min) or, liver failure; immunodeficiency or autoimmune conditions; anyone 109 
prescribed long-term antibiotics (including azithromycin), aminophylline, maintenance 110 
oral steroids, or other immunosuppressive medications. We included patients 111 
prescribed inhaled corticosteroids (ICS), anticholinergics and long- and short-acting 112 
beta agonists. All patients were prescribed optimal medication for their COPD 113 
according to current guidelines [1] and all were deemed clinically stable with none 114 
reporting a worsening of symptoms (no exacerbation) in the previous 3 months. 115 
Sample collection and haematological analysis 116 
Participants provided 10 ml of blood (K3EDTA and Lithium-Heparin) from the 117 
antecubital vein. Total and differential leukocyte counts and platelets were recorded 118 
on K3EDTA anticoagulated whole blood using an automated hematology analyser 119 
(ADVIA 2120, Siemens Healthcare Diagnostics GmbH, Eschborn, Germany).  120 
Neutrophil assays 121 
As described previously [21], neutrophil phorbol-12-myristate-13-acetate(PMA)- and 122 
formyl-methionyl-leucyl-phenylalanine(fMLP)-stimulated oxidative burst were 123 
assessed by a chemiluminescence (CL) kit (ABEL®04M, Knight Scientific Ltd, 124 
Plymouth, UK) incorporating the light-emitting protein Pholasin®. The CL per well 125 
was measured by a microplate luminometer (FLUOstar OPTIMA, BMG Labtech, 126 
Aylesbury, UK). Each well contained: 10 µL of diluted whole (K3EDTA) blood (ratio of 127 
1:100 with Hank’s balanced salt solution; HBSS, without calcium and magnesium), 128 
90 µL assay buffer (HBSS with calcium and magnesium), 50 µL Pholasin and 20 µL 129 
adjuvant K. These mixtures were gently shaken and incubated at 37 °C for 30 s in 130 
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the luminometer, prior to the addition of 20 µL of PMA (5 µg/mL), 20 µL fMLP (10 µM) 131 
(or additional 20 µL of HBSS for unstimulated wells) to provide an end total volume of 132 
200 µL per well, a 1:1010 final blood dilution and stimulated wells containing a PMA 133 
or fMLP concentration of 0.5 µg/mL or 1 µM. These concentrations have been 134 
standardised to be not rate limiting, even in the presence of abnormally high numbers 135 
of leukocytes, and thus provide responses that are reproducible. For PMA, CL of 136 
stimulated and unstimulated replicates of the same samples were recorded as 137 
relative light units (RLU) at 20 s intervals for 30 min. For fMLP, CL was recorded 138 
every second for 300 s. The area under the unstimulated CL curves was subtracted 139 
from stimulated curves of the same sample to determine PMA- or fMLP-stimulated 140 
oxidative burst. To calculate responses on a per cell basis in whole blood, area under 141 
the CL curve was expressed to number of neutrophils (in well) only as the 142 
contributions of monocytes, eosinophils and basophils in our 1:1010 final dilution of 143 
blood are considered to be insignificant [21,22]. 144 
Neutrophil stimulated degranulation was determined as previously described [23]. 145 
Heparinised blood (1 mL) was added to a microcentrifuge tube with 50 µL bacterial 146 
stimulant containing Staphococcus aureus, Psuedomonas fluorescens and 147 
Aerobacter aerogenes (840-15, Sigma, Poole, UK). The microcentrifuge tubes were 148 
initially mixed by gentle inversion before incubation at 37 °C for 1 h (all tubes also 149 
mixed halfway through). Following incubation, the tubes were centrifuged for 2 min at 150 
16 000 g, with the supernatant being immediately removed and stored at −80 °C until 151 
further analysis. Following thawing at room temperature, α1-proteinase inhibitor(α1-152 
PI)/neutrophil elastase(NE) complex was measured in all samples using an ELISA kit 153 
(Calbiochem®, Merck, Darmstadt, Germany). Bacterial-stimulated degranulation was 154 
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based on subtracting α1-PI/NE of unstimulated samples (heparinized plasma at 155 
same time point) away from stimulated samples and expression per neutrophil.  156 
Statistical analysis 157 
Statistical analysis was performed using SPSS (v21.00; SPSS Inc., Chicago, IL, 158 
USA). Normality was tested using the Shapiro-Wilk test and statistical significance 159 
was taken as p < 0.05. Primary outcome measures were stimulated neutrophil 160 
function. Data were analyzed between groups using one-way analysis of variance 161 
and independent t-tests or Kruskal-Wallis and Mann Whitney U tests. Relationship 162 
between baseline neutrophil count and daily beclamethasone dose with neutrophil 163 
function were assessed using Pearson correlation. For categorical data (gender) 164 
Fisher’s exact test was applied. 165 
Results 166 
Clinical characteristics and blood leukocytes 167 
Clinical details and total and differential leukocyte counts are summarised in Table 1. 168 
As expected FEV1 was significantly greater in healthy controls compared to both 169 
COPD groups (p < 0.001). No significant differences were found between COPD 170 
frequent exacerbators and non-exacerbators in FEV1, prescribed daily 171 
beclamethasone equivalent dose and leukocyte counts (p > 0.05). 172 
9 
 
 
Neutrophil oxidative burst 173 
Both COPD frequent exacerbators and non-exacerbators had lower fMLP-stimulated 174 
oxidative neutrophil burst compared to controls, with frequent exacerbators also 175 
showing significantly lower function compared to non-exacerbators (Fig. 1). 176 
Neutrophil PMA-stimulated oxidative burst was significantly lower in both COPD 177 
groups compared to controls (Fig. 2). However, there was no significant difference 178 
between frequent exacerbators and non-exacerbators COPD for responses to PMA 179 
(p = 0.45). To help determine the effect of baseline inflammatory status on 180 
subsequent neutrophil responsiveness, we investigated whether ICS exposure or 181 
baseline blood neutrophil count correlated with measures of neutrophil function.  182 
There were no correlations between fMLP-stimulated response and baseline 183 
neutrophil count (p = 0.42), or between fMLP-stimulated response and daily 184 
beclamethasone equivalent dose (p = 0.17). There were no correlations between 185 
PMA-stimulated oxidative burst and baseline neutrophil count (p = 0.791) or between 186 
PMA-stimulated responses and daily beclamethasone equivalent dose (p = 0.30). 187 
Neutrophil degranulation 188 
Blood neutrophils of COPD frequent exacerbators showed heightened bacterial-189 
stimulated degranulation (α1-PI/NE complex) compared to non-exacerbator COPD 190 
(Fig. 3). Although there was no correlation between baseline neutrophil count and 191 
stimulated concentrations of α1-PI/NE complex (p = 0.880), there was a significant 192 
positive correlation between daily beclamethasone equivalent dose and bacterial-193 
stimulated degranulation (p = 0.04, r = 0.298). 194 
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Discussion 195 
In the present study, we showed that blood neutrophil oxidative burst is blunted in 196 
COPD with receptor-dependent ROS production showing greater impairment in the 197 
frequent exacerbator phenotype. Assessment of total degranulation responses of 198 
blood neutrophils showed further dysregulation associated with the exacerbator 199 
phenotype. 200 
To the best of our knowledge, this is the first report of distinct patterns of neutrophil 201 
function that relate to COPD exacerbation phenotype whilst in a stable state. We do 202 
not prove mechanistically that changes in neutrophil effector functions are the causes 203 
of or as a result of frequent exacerbations but provide an important starting point for 204 
future investigations.  205 
This study supports previously reported evidence of reduced intracellular oxidative 206 
burst to fMLP in COPD populations compared to healthy counterparts {15, 24]. 207 
Impaired chemotactic responses to fMLP have also been observed in moderate-208 
severe COPD, compared to healthy smokers and non-smokers as well as COPD 209 
patients with milder airflow obstruction [16]. These impaired functional responses to 210 
stimulants are consistent with poor resistance to infection in COPD. Like us, these 211 
other studies suggest greater severity of disease is not related with augmented 212 
activity of inflammatory cells but a down-regulation. Our study, however, suggests 213 
there are certain clinical phenotypes, which show further changes in neutrophil 214 
responses to inflammatory stimuli (bacterial peptides) that may partly explain their 215 
intrinsic susceptibility to recurrent infectious episodes. Blood neutrophils in COPD 216 
demonstrate reduced migratory accuracy towards fMLP and decreased structural 217 
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changes and sensitivity to such chemotactic factors under receptor occupancy [14]. 218 
Aberrant blood neutrophil responses in COPD appear to be due to intrinsic cell defect 219 
(e.g. intracellular enzymatic reactions and kinases) rather than cell surface 220 
expression of chemoattractant receptors [14].. Further investigation (utilising whole 221 
blood flow cytometry) of immune regulation events upstream (e.g. at the level of 222 
FPR1 receptor) and downstream of neutrophil activation would help understand the 223 
interpretation and significance of impaired fMLP–stimulated oxidative burst in the 224 
frequent exacerbator. 225 
Our findings of reduced blood neutrophil PMA-oxidative burst in COPD contrast with 226 
earlier reports of greater ROS production compared to controls [26, 27]. Differences 227 
in results could be explained by study participants (including the differences in 228 
treatment (e.g. non-ICS users in [26, 27]) or characteristics of the sampling and 229 
assays. For example, Renkema et al. [26] used heparinised samples (as opposed to 230 
EDTA), which have been demonstrated to interfere with neutrophils prior to 231 
subsequent activation of oxidative burst [28, 29]. Previous studies (26, 27) had also 232 
used isolation procedures that are known to influence neutrophil activation (including 233 
density gradient centrifugation, fluctuations in temperature) prior to any staining and 234 
in vitro stimulation. Our approach, using whole blood, provides minimal manipulation 235 
of cells and provides a more accurate representation of neutrophil behaviour in vivo 236 
(i.e. better maintenance of the extracellular milieu) [30]. In contrast to fMLP, we did 237 
not observe differences between exacerbation phenotypes in PMA-stimulated 238 
oxidative burst. Unlike the G-coupled receptor-dependent responses to fMLP, PMA 239 
penetrates the cell (independent of a receptor), triggering a long lasting, strong 240 
stimulation via protein kinase C and activation of NADPH oxidase throughout the cell. 241 
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PMA is considered an artificial stimulus (not encountered in vivo), differing 242 
substantially to physiological agonists (e.g. fMLP) [31]. Although PMA-stimulated 243 
responses provides further evidence of the aberrant intracellular signalling in COPD, 244 
such cell activation lacked biological sensitivity to characterise COPD phenotypes 245 
that may differ in their ability to recognise microbial moieties (e.g. formylated 246 
peptides) and mount responses toward infectious/inflammatory challenge [32].  247 
COPD blood neutrophils possess exaggerated innate immune responses to Toll-like 248 
receptor (TLR) agonists (e.g. lipopolysaccharide) [33]. Upon triggering neutrophil 249 
degranulation, the concentration of free NE increases for only a brief period of time 250 
as its major inhibitors (e.g. α1-PI) rapidly reach reaching equimolar concentrations 251 
[34]. Measurement of α1-PI/NE complexes is considered to be marker of total NE 252 
release during neutrophil degranulation [35]. Here, we suggest that such heightened 253 
responses to TLR agonists (in our case both gram-positive and gram-negative 254 
bacteria) are more reflective of a COPD frequent exacerbator. These findings appear 255 
contradictory to the data on fMLP, whereby both fMLP-stimulated oxidative burst 256 
(e.g. FRP1) and bacterial-stimulated degranulation (e.g. TLR2, TLR4) represent 257 
receptor-mediated events. Similar differences between circulating phagocyte 258 
responses to chemoatttractants and pro-inflammatory mediators have been observed 259 
in COPD [36]. Although distinct and complex intracellular transduction pathways are 260 
involved, one plausible mechanism for the observed variability between neutrophil 261 
effector functions in our study is the selective effect of ICS on one of the neutrophil 262 
function pathways (α1-PI/NE). In COPD patients stratified according to GOLD 263 
severity, increasing ICS dosage was associated with enhanced stimulated neutrophil 264 
degranulation [37]. Budesonide and fluticasone propionate prolong human neutrophil 265 
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survival by inhibiting apoptosis at clinically relevant drug concentrations [38]. We 266 
speculate that the greater (albeit non-significant) mean beclamethasone exposure of 267 
the frequent exacerbators may partly explain the heightened NE release of 268 
stimulated blood neutrophils in the frequent exacerbator.  269 
Strengths of our study include its real-life setting using recognised clinical 270 
phenotypes of COPD. Our findings are generalizable with patient demographics 271 
reflecting patients with moderate-to-severe disease that attend a standard secondary 272 
care service. The greater proportion of patients prescribed ICS in frequent 273 
exacerbators corroborates previous findings [11] and reflects current treatment 274 
guidelines [1]. Our number of participants is comparable to most other biological 275 
studies comparing neutrophil responses in COPD. We also validated and controlled 276 
for smoking status and used a healthy control group as an additional reference point.  277 
The cross-sectional methodology does not allow us to identify whether responses of 278 
the frequent exacerbator represent an intrinsic or acquired defect of neutrophil 279 
function. The primary aim of this study was to characterise blood neutrophil function 280 
(in the stable state) in COPD exacerbation phenotypes and not the temporal nature 281 
of the relationship between inflammatory mediators and onset of COPD 282 
exacerbations investigated previously [39]. We did not sample airway neutrophils to 283 
compare against blood, however, others propose the dysregulation of immune 284 
function in COPD frequent exacerbators may be systemic rather than a specific 285 
abnormality limited to the lungs [12].  286 
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Conclusions 287 
In conclusion, we have demonstrated aberrant blood neutrophil functions in COPD, 288 
highlighting alterations in receptor-dependent responses that relate to the frequent 289 
exacerbator phenotype. Frequent exacerbators have impaired oxidative responses to 290 
chemotactic factors and augmented degranulation responses to bacterial triggers in 291 
the circulation. Importantly, this study provides further support to a biological 292 
underpinning of the frequent exacerbator phenotype and provides insights into 293 
immune cell defects that can act as the basis for future investigations. 294 
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Table 1 Clinical characteristics of study participants.  420 
 Data are presented as mean ± standard deviation or median (interquartile range). 421 
FEV1: forced expiratory volume in 1 s.   422 
 
Parameter 
Healthy 
control 
(n = 8) 
COPD 
non-exacerbator 
(n = 18) 
COPD 
frequent exacerbator 
(n = 26) 
 
p-value 
Age, yrs 63.3 ± 7.6 68.7 ± 7.7 65.0 ± 7.5 0.15 
Males / females, n 6/2 11/7 17/9 0.80 
FEV1, L 2.7 ± 0.4 1.0 ± 0.3 1.0 ± 0.5 <0.01 
FEV1, % predicted  89.7 ± 8.5 38.5 ± 10.8 36.6 ± 13.4 <0.01 
Daily beclamethasone equivalent, µg  800 (0, 2000) 1500 (950, 2000) 0.14 
Total leukocytes, 109L-1  7.0 (6.3, 7.7) 9.1 (6.9, 10.7) 7.1 (6.2, 8.9) 0.13 
Neutrophils, 109L-1  4.0 (3.7, 4.7) 6.0 (4.3, 7.4) 4.6 (4.0, 6.3) 0.05 
Monocytes, 109L-1 0.5 (0.4, 0.7) 0.5 (0.4, 0.6) 0.5 (0.3, 0.8) 0.70 
Total lymphocytes, 109L-1  1.7 (1.6, 2.1) 1.7 (1.2, 2.2) 1.6 (1.0, 2.1) 0.51 
Neutrophil: lymphocyte ratio  2.3 (1.8, 2.9) 3.6 (2.6, 5.1) 3.2 (2.0, 4.8) 0.06 
Platelets, 109L-1 236 (221, 333) 284 (246, 389) 289 (238, 380) 0.53 
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Fig. 1 Neutrophil fMLP-stimulated oxidative burst (chemiluminescence) responses. 423 
Columns indicate mean values for each group. Error bars represent standard 424 
deviation. Significant difference between groups: *p< 0.05, **p < 0.01, ***p < 0.001 425 
Fig. 2 Neutrophil PMA-stimulated oxidative burst (chemiluminescence) responses. 426 
Columns indicate mean values for each group. Error bars represent standard 427 
deviation. Significant difference between groups: **p < 0.01, ***p < 0.001 428 
Fig. 3 Bacterial-stimulated neutrophil degranulation (α1-proteinase inhibitor/ 429 
neutrophil elastase). Columns indicate mean values for each group. Error bars 430 
represent standard deviation. Significant difference between groups: *p< 0.05   431 
